That is the point specialneeds was making. The costs of litigation are mostly borne by the target company, not the class action shareholders. Its the legal expenses that OWC will face is the big problem, major trouble if found to have contributed to the situation by approving the release of the shares. That is not a SEC issue, more an issue for civil damages.
Thank you for sharing your wisdom and experience with the board. One think that should be focused is this....An extremely undervalued BioTech like OWCP with over 22 registered patents and a great management team of scientists is not going anywhere in any situation. It may exchange hands if has to (which I highly doubt) but that would also be at a much higher price.
Team members may come and go but those 20+ registered patents and OWCP's IP is here to stay and those are the ones that will eventually drive the company's value to stardom.